T Cell Therapy Clinical Trials

23 recruitingLast updated: June 18, 2026

There are 23 actively recruiting t cell therapy clinical trials across 6 countries. Studies span Phase 1, Not Applicable, Early Phase 1, Phase 2. Top locations include Hangzhou, Zhejiang, China, Tianjin, Tianjin Municipality, China, Guangzhou, Guangdong, China. Updated daily from ClinicalTrials.gov.


T Cell Therapy Trials at a Glance

23 actively recruiting trials for t cell therapy are listed on ClinicalTrialsFinder across 6 cities in 6 countries. The largest study group is Phase 1 with 9 trials, with the heaviest enrollment activity in Hangzhou, Tianjin, and Guangzhou. Lead sponsors running t cell therapy studies include The Children's Hospital of Zhejiang University School of Medicine, Miltenyi Biomedicine GmbH, and Institute of Hematology & Blood Diseases Hospital, China.

Browse t cell therapy trials by phase

Treatments under study

About T Cell Therapy Clinical Trials

Looking for clinical trials for T Cell Therapy? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new T Cell Therapy trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about T Cell Therapy clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 23 trials

Recruiting
Early Phase 1

Exercise as an Immune Adjuvant for Allogeneic Cell Therapies

LymphomaLeukemiaCAR-T Cell Therapy+3 more
University of Arizona200 enrolled1 locationNCT06643221
Recruiting
Early Phase 1

Dual Target CAR-T Cell Treatment for Refractory Systemic Lupus Erythematosus (SLE) Patients

CAR-T Cell Therapy
RenJi Hospital18 enrolled1 locationNCT05858684
Recruiting
Phase 1Phase 2

MB-CART2019.1 in Refractory Multiple Sclerosis

Multiple SclerosisCAR-T Cell Therapy
Miltenyi Biomedicine GmbH26 enrolled1 locationNCT07178431
Recruiting
Not Applicable

Nutrition OUtReach In Systems of Healthcare

CAR-T Cell TherapyALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATIONFood Insecurity+1 more
University of Kansas Medical Center210 enrolled4 locationsNCT06802406
Recruiting
Not Applicable

Coping Skills Training for Symptom Management and Daily Steps (Step Up)

Hematopoietic Stem Cell TransplantCAR-T Cell Therapy
Duke University177 enrolled1 locationNCT06575712
Recruiting
Not Applicable

THRIVE-CAR-T Digital App

CAR-T Cell Therapy
Patrick C. Johnson, MD100 enrolled1 locationNCT06665295
Recruiting
Phase 2

DALY II Japan/MB-CART2019.1 for DLBCL

DLBCL - Diffuse Large B Cell LymphomaCAR-T Cell Therapy
Miltenyi Biomedicine GmbH31 enrolled5 locationsNCT07288879
Recruiting
Phase 1

RE002 T Cell Injection for the Treatment of KRAS G12D Mutated Solid Tumors

KRAS G12DT Cell Therapy
Henan Cancer Hospital30 enrolled1 locationNCT06546150
Recruiting

A Safety and Efficacy Long-Term Follow-up Study of Adult Participants Treated With Gene Modified T Cells

Long Term Safety Following GM T Cell Therapy
Regeneron Pharmaceuticals50 enrolled1 locationNCT06798298
Recruiting
Early Phase 1

TC-D101 Cell Therapy for Patients With DLL3-Positive SCLC

Small Cell Lung Cancer ( SCLC )CAR-T Cell Therapy
TCRCure Biopharma Ltd.24 enrolled1 locationNCT07246304
Recruiting

Neuroimaging and Biomarkers of Neurotoxicity After Chimeric Antigen Receptor T-Cell Therapy

CAR-T Cell Therapy
University of California, San Diego36 enrolled1 locationNCT07075523
Recruiting
Phase 1

A Study of A-CAR028 Treatment in Subjects With Relapsed or Refractory Acute Myeloid Leukemia

CAR-T Cell TherapyAcute Myeloid Leukemia (AML)
First Affiliated Hospital of Zhejiang University20 enrolled1 locationNCT07198867
Recruiting
Phase 1

Study of Therapeutic Efficacy of CAR-T Cell Therapy in Patients With MDR-SRNS

CAR-T Cell TherapyMulti-Drug Resistant Nephrotic Syndrome
The Children's Hospital of Zhejiang University School of Medicine18 enrolled1 locationNCT06553898
Recruiting
Not Applicable

Anti CD19 CAR-T Combined With BTKi to Treat Newly Diagnosed High-risk CLL/SLL

CAR-T Cell TherapyCLLSLL
The Affiliated Hospital of Xuzhou Medical University50 enrolled1 locationNCT07120633
Recruiting

Brain Function and Psychological Changes Related to Cell Therapy for Autoimmune Hemolytic Anemia

Brain functionCAR-T Cell TherapyAutoimmune Hemolytic Anemia+1 more
Institute of Hematology & Blood Diseases Hospital, China20 enrolled1 locationNCT06921980
Recruiting
Phase 1

CD7 CAR T Cells (RD13-02) in the Treatment of Relapsed/Refractory Severe Aplastic Anemia

RelapseCAR-T Cell TherapyRefractory+1 more
Institute of Hematology & Blood Diseases Hospital, China15 enrolled1 locationNCT06622694
Recruiting
Phase 1

Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cell Therapy in Patients With MDR-SRNS

CAR-T Cell TherapyMulti-Drug Resistant Nephrotic Syndrome
The Children's Hospital of Zhejiang University School of Medicine18 enrolled1 locationNCT06842589
Recruiting
Phase 1

Study of BCMA/CD70 CAR-T Therapy for Refractory cSLE

CAR-T Cell TherapySystemic Lupus ErythematosusBCMA
The Children's Hospital of Zhejiang University School of Medicine18 enrolled1 locationNCT06934447
Recruiting

Study of Extracellular Vesicles (EV) in Patients Undergoing CAR-T Cell Therapies

CAR-T Cell TherapyExtracellular Vesicles
IRCCS Azienda Ospedaliero-Universitaria di Bologna100 enrolled1 locationNCT06554951
Recruiting

Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Children With Refractory Refractory AAV

CAR-T Cell TherapyANCA-associated Vasculitis
The Children's Hospital of Zhejiang University School of Medicine12 enrolled1 locationNCT06508346